Current Report Filing (8-k)
18 May 2020 - 8:14PM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 14, 2020
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
incorporation or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, no par value
|
|
AKER
|
|
The
NASDAQ Capital Market
|
Item
8.01 Other Events.
As
previously reported, on May 14, 2020, Akers Biosciences, Inc. (the “Company”) entered into a Securities Purchase
Agreement with certain institutional and accredited investors, pursuant to which the Company agreed to issue and sell in a registered
direct offering (the “Offering”) an aggregate of 1,366,856 shares (the “Shares”) of common stock of the
Company, no par value, at an offering price of $3.53 per share, for gross proceeds of approximately $4.825 million before the
deduction of placement agent fees and offering expenses. The Shares were offered by the Company pursuant to a shelf registration
statement on Form S-3 (File No. 333- 234449) (the “Shelf Registration Statement”), which was initially filed with
the Securities and Exchange Commission (the “Commission”) on November 1, 2019, and was declared effective by the Commission
on April 7, 2020, and a related prospectus.
On
May 18, 2020, the Company filed a prospectus supplement, dated May 14, 2020, to the Shelf Registration Statement, covering the
Offering.
The
legal opinion of Haynes and Boone, LLP relating to the legality of the issuance and sale of the Shares in the Offering is attached
as Exhibit 5.1 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
Dated:
May 18, 2020
|
/s/
Christopher C. Schreiber
|
|
Christopher
C. Schreiber
|
|
Executive
Chairman of the Board of Directors and Director
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Akers Biosciences Inc (NASDAQ): 0 recent articles
More Akers Biosciences, Inc. News Articles